List of Excipients in Branded Drug ENTRESTO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	ENTRESTO	sacubitril and valsartan	0078-0659	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	ENTRESTO	sacubitril and valsartan	0078-0659	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	ENTRESTO	sacubitril and valsartan	0078-0659	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	ENTRESTO	sacubitril and valsartan	0078-0659	FERROSOFERRIC OXIDE

ENTRESTO Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

Entresto, the sacubitril/valsartan combination marketed by Novartis, is a high-value small-molecule product with an excipient platform built around conventional direct-compression materials. Its main commercial opportunities are generic and 505(b)(2) development, pediatric delivery, formulation differentiation, supply-chain substitution, and excipient-enabled manufacturing improvements. The strongest opportunities are in low-moisture processing, bioequivalent tablet manufacture, sprinkle or multiparticulate delivery, and differentiated dosage forms that address swallowing and titration needs.

What excipients are used in Entresto tablets?

The U.S. Entresto tablet contains conventional tablet-core and film-coating excipients. The FDA-approved labeling identifies the following functional categories and materials.[1]

Formulation element	Reported excipient or category	Primary function
Tablet filler	Microcrystalline cellulose	Compressibility, tablet mass, mechanical strength
Binder and disintegrant support	Low-substituted hydroxypropylcellulose	Disintegration and compactability
Superdisintegrant	Crospovidone	Rapid tablet breakup and dissolution
Lubricant	Magnesium stearate	Ejection and reduction of tooling friction
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Anti-adherent or processing aid	Talc	Flow, adhesion control, coating performance
Film former	Hypromellose	Tablet coating and protection
Coating aid or plasticizer	Polyethylene glycol	Film flexibility and processing
Opacifier	Titanium dioxide	Appearance and light protection
Colorants	Iron oxides	Strength and product identification

The exact excipient composition can vary by market, strength, and dosage presentation. Entresto is marketed in multiple tablet strengths, including 24/26 mg, 49/51 mg, and 97/103 mg, where the figures represent sacubitril/valsartan content.[1]

The formulation uses a conventional excipient architecture rather than a lipid system, amorphous solid dispersion, modified-release matrix, or complex solubilization technology. That creates a relatively accessible pathway for generic manufacturers, but the combination product still presents technical challenges in assay, dissolution, blend uniformity, and active-ingredient interaction.

How does the Entresto formulation affect excipient selection?

The primary formulation issue is the presence of two active pharmaceutical ingredients with different physical and chemical properties. Sacubitril and valsartan are administered as a fixed combination, and the product must deliver both components consistently across strengths.

Excipient selection must address four technical requirements:

1. Uniform distribution of both active ingredients.
2. Consistent tablet compression across low and high strengths.
3. Rapid and reproducible disintegration.
4. Stability under moisture, heat, and mechanical stress.

Microcrystalline cellulose and low-substituted hydroxypropylcellulose provide a conventional platform for direct compression or dry granulation. Crospovidone supports rapid disintegration without requiring prolonged wet granulation. Colloidal silicon dioxide can improve flow where the active blend has poor bulk density or cohesiveness.

Moisture and chemical stability

A low-moisture process is commercially attractive because valsartan-containing systems can be sensitive to degradation pathways associated with heat, humidity, and reactive formulation environments. A manufacturer evaluating an alternative excipient system should prioritize:

• Low-water-activity grades of fillers and disintegrants.
• Controlled relative humidity during blending and compression.
• Low-peroxide grades of povidone or crospovidone where relevant.
• Packaging with high moisture-barrier performance.
• Compatibility screening for aldehydes, peroxides, alkaline materials, and metal impurities.

A direct-compression formulation can reduce exposure to aqueous processing, but it places greater demands on powder flow, segregation control, and tablet-weight uniformity. Roller compaction may offer a useful alternative when the blend requires density improvement without water exposure.

Blend uniformity and dose proportionality

Entresto contains a fixed ratio of two active ingredients, while tablet strengths differ substantially in total drug load. The lowest strength is especially important because the amount of active material is smaller relative to the excipient mass. Content-uniformity risk can increase if the active ingredients differ in particle size, density, electrostatic behavior, or surface energy.

Potential controls include:

• Narrow particle-size distributions for both active ingredients.
• Separate deagglomeration and screening steps.
• Ordered mixing or carrier-based blending.
• In-line weight and content monitoring.
• Segregation testing after hopper discharge and tablet compression.
• Strength-specific rather than fully dose-proportional formulations.

A generic manufacturer does not need to copy the reference product’s excipients exactly. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway, while controlling critical quality attributes such as dissolution, assay, impurities, and content uniformity.[2]

What commercial opportunities exist for Entresto excipient suppliers?

The largest opportunity is not a single novel excipient. It is a qualified, reproducible supply package for manufacturers entering the generic market.

Excipient substitution and dual sourcing

Generic manufacturers may seek second sources for:

• Microcrystalline cellulose.
• Crospovidone.
• Low-substituted hydroxypropylcellulose.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Hypromellose coating systems.
• Iron-oxide colorants.

Supplier value will depend on regulatory documentation, lot-to-lot consistency, global availability, and technical support. Excipients with multiple compendial monographs and a well-established regulatory history have a commercial advantage because they reduce formulation and filing risk.

Direct-compression excipient platforms

A supplier can package a co-processed or engineered excipient system around:

• Improved flow.
• Higher compactability.
• Lower lubricant sensitivity.
• Reduced segregation.
• Faster disintegration.
• Lower sensitivity to compression-force changes.

The commercial proposition is strongest where the platform reduces development time or increases tablet throughput. However, a co-processed excipient can create additional characterization and regulatory work if its composition or manufacturing process is not fully covered by established excipient data.

Coating systems

Color-coded film coating is important for strength differentiation and product identification. Ready-to-use coating systems can reduce scale-up burden and improve visual consistency across global markets. Opportunities include:

• Lower-solids coating systems.
• Faster drying at reduced inlet temperatures.
• Titanium-dioxide-reduced or titanium-dioxide-free systems where regional rules require alternatives.
• High-barrier coatings for humidity-sensitive products.
• Color systems compatible with pediatric sprinkle or multiparticulate products.

What formulation patents protect Entresto?

Entresto’s core protection is primarily associated with the sacubitril/valsartan combination, pharmaceutical compositions, and methods of treatment rather than ownership of standard excipients such as microcrystalline cellulose or magnesium stearate.

The FDA Orange Book has historically listed patents for Entresto-related composition and use claims. Public patent records identify U.S. Patent No. 8,734,876 as a key patent associated with the sacubitril/valsartan pharmaceutical combination. Its listed expiration was in 2026, subject to applicable patent-term adjustment, patent-term extension, pediatric exclusivity, and Orange Book status.[3]

A generic formulation using different excipients does not automatically avoid composition or method-of-use claims. Conversely, use of the same conventional excipients does not by itself establish infringement. FTO analysis should separate:

• Active-ingredient combination claims.
• Salt, complex, or solid-state claims.
• Pharmaceutical-composition claims.
• Tablet or multiparticulate formulation claims.
• Pediatric administration claims.
• Heart-failure treatment claims.
• Process and manufacturing claims.

The existence and scope of any formulation-specific claims must be assessed against current patent records and claim construction. Standard excipients generally provide weak standalone patent barriers, but a particular ratio, process, particle engineering approach, or delivery system can support a narrower formulation patent.

When does Entresto lose exclusivity?

Entresto received FDA approval on July 7, 2015.[1] Its initial regulatory exclusivity period has expired. The product’s commercial exposure is therefore driven mainly by patents, pediatric exclusivity, ANDA approvals, litigation, settlements, and the timing of generic launches.

Exclusivity or market event	Approximate timing	Commercial effect
FDA approval	July 2015	Start of commercial life
Initial small-molecule regulatory exclusivity	2020	ANDA filing and approval activity could begin, subject to patent barriers
Pediatric exclusivity extension	Applied after qualifying pediatric obligations	Extended certain exclusivity periods by six months
Key patent expiry window	2026 range for major early U.S. protection	Potential broad generic entry point, subject to litigation and settlements
Post-patent market	After applicable patent barriers	Price erosion and multi-source generic competition likely

Entresto is not a biologic. Biosimilar rules do not apply. Generic competitors would normally use the ANDA pathway, with paragraph IV certifications used to challenge listed patents.[2]

Which companies are challenging Entresto exclusivity?

Entresto generic competition is expected to come from established generic companies with cardiovascular portfolios and sufficient capacity for complex fixed-dose combination manufacturing. Public patent challenges and ANDA activity should be evaluated through FDA Orange Book records, Paragraph IV notices, and federal court dockets.

A company can challenge Entresto through several routes:

• Paragraph IV certification against listed patents.
• Section viii statement for non-patented indications.
• ANDA filing with a non-infringing formulation.
• 505(b)(2) application for a differentiated dosage form.
• Post-expiry launch using the reference formulation as a development benchmark.

The commercial significance of a Paragraph IV challenge depends on whether the challenger is first to file, whether the patent holder sues within the statutory period, whether a 30-month stay applies, and whether a settlement creates an authorized or licensed launch date.[2]

What is the Orange Book status of Entresto?

The Orange Book identifies Entresto as a prescription fixed-dose combination product with listed patents and exclusivity information. The Orange Book is relevant to ANDA strategy because it defines the patents that applicants must address through paragraph IV, paragraph III, or section viii certifications.

For commercial analysis, the key Orange Book questions are:

1. Which patents remain listed for each Entresto strength and dosage form?
2. Which patents have expired or been delisted?
3. Does pediatric exclusivity alter the effective blocking date?
4. Are Sprinkle or pediatric presentations protected separately?
5. Which method-of-use patents are relevant to proposed labeling?

An excipient strategy should be developed alongside the Orange Book review. Changing excipients may reduce formulation-specific risk, but it will not necessarily avoid patents covering the active combination, a salt or complex, or a treatment method.

What formulations are protected or commercially differentiated?

Standard immediate-release tablets

The standard tablet is the most direct generic opportunity. A conventional immediate-release product can compete on cost, manufacturing efficiency, and supply reliability. The formulation challenge is achieving comparable dissolution without copying every inactive ingredient.

Pediatric sprinkle formulation

Novartis introduced an Entresto Sprinkle formulation for pediatric patients. A sprinkle presentation can improve administration for children who cannot swallow tablets and creates a more specialized development opportunity than a conventional tablet.[4]

A competitive sprinkle product could use:

• Multiparticulate granules.
• Taste-masking polymers.
• Swallowable capsule contents.
• Food-compatible particles.
• Low-moisture packaging.
• Dose-flexible sachets or unit-dose presentations.

Pediatric products require careful control of particle size, taste, dose uniformity, stability after opening, and compatibility with permitted foods or liquids. The regulatory pathway may be more complex than a standard ANDA if the dosage form or labeling does not fit the reference product.

Orally disintegrating and liquid presentations

An orally disintegrating tablet could target patients with swallowing difficulty, although the high drug load and dual-active formulation may create tablet-size and taste constraints. A liquid or suspension product could permit dose titration, but it would require robust control of solubility, physical stability, sedimentation, preservative compatibility, and palatability.

These products are more likely to support a 505(b)(2) strategy than a straightforward ANDA unless the reference product and proposed presentation align closely with FDA requirements.

How strong is the Entresto patent estate?

The patent estate is commercially meaningful because Entresto generates multibillion-dollar sales and combines two active ingredients in a high-value cardiovascular indication. Its strength depends less on ordinary excipient claims and more on the breadth and timing of active-combination, composition, solid-state, and method-of-use protection.

Estate component	Strategic strength	Relevance to excipient strategy
Sacubitril/valsartan combination claims	High where unexpired and valid	Excipients generally do not avoid these claims
Pharmaceutical-composition claims	Moderate to high depending on claim scope	Alternative excipient systems may help only if claims are narrow
Method-of-use claims	Indication-dependent	Label carve-outs may reduce risk in some cases
Pediatric formulation claims	Potentially narrow but commercially important	Sprinkle and multiparticulate development requires separate review
Standard excipient claims	Generally limited	Supplier differentiation depends more on performance and documentation
Manufacturing claims	Variable	Dry processing and particle engineering may create design-around issues

Patent strength also depends on validity challenges, prosecution history, obviousness arguments, written-description support, and the enforceability of any listed patent. A high sales base increases the financial incentive for both paragraph IV challenges and settlement negotiations.

What generic launch risks exist for Entresto?

The main launch scenarios are:

Early settlement launch

A generic company may obtain a licensed or settlement-based launch date before full patent expiry. The agreement may include restrictions on launch timing, dosage forms, or authorized-generic competition. Settlement terms can materially change the value of excipient investments because a delayed launch reduces the period available to recover development and scale-up costs.

Single-challenger launch

A first successful paragraph IV challenger may obtain a period of commercial advantage, depending on the statutory and regulatory circumstances. This scenario increases the value of a fully qualified excipient supply chain before litigation resolution.

Multi-source launch after patent expiry

Once major patent barriers expire, several manufacturers may enter rapidly. Price erosion is likely to be substantial, making conversion cost, yield, throughput, and supplier pricing more important than formulation novelty.

Delayed or blocked launch

A generic may receive approval but remain unable to market the product because of litigation, settlement restrictions, unresolved use patents, or manufacturing deficiencies. Excipient suppliers can reduce exposure by supporting multiple potential applicants rather than relying on a single launch partner.

How does Entresto compare with other cardiovascular combination products?

Entresto differs from many conventional cardiovascular fixed-dose combinations because it combines an angiotensin receptor blocker with neprilysin inhibition and has a comparatively high commercial value per product. It also has a pediatric delivery requirement that is less common among adult cardiovascular products.

Attribute	Entresto	Conventional antihypertensive combination
Active ingredients	Sacubitril and valsartan	Often two established antihypertensives
Main generic route	ANDA, subject to patent certifications	Usually ANDA
Biosimilar exposure	None	None
Formulation complexity	Moderate, with dual-active compatibility needs	Often lower
Pediatric opportunity	Meaningful because of sprinkle formulation	Variable
Patent exposure	Combination, composition, use, and presentation claims	Frequently narrower after legacy patent expiry
Excipient opportunity	Stability, blend uniformity, pediatric delivery	Cost reduction and standard tablet optimization

What are the licensing and partnership opportunities?

Licensing opportunities are most credible in four areas:

1. Pediatric sprinkle or multiparticulate technology.
2. Taste masking and food-compatible delivery.
3. Excipient systems that improve direct compression or dry granulation.
4. Regional generic commercialization after patent or settlement milestones.

A technology owner should avoid presenting ordinary use of microcrystalline cellulose or crospovidone as a defensible licensing asset. The stronger proposition is a validated formulation or process package that improves a measurable attribute, such as dissolution robustness, tablet hardness, moisture stability, or content uniformity.

Potential counterparties include generic manufacturers, contract development and manufacturing organizations, excipient suppliers, pediatric-product specialists, and regional licensees. Commercial agreements should define responsibility for bioequivalence, DMF support, change control, alternate suppliers, and post-approval formulation modifications.

What is the FDA regulatory status of Entresto?

Entresto is FDA-approved for adult heart failure indications and has an approved pediatric use and sprinkle presentation.[1,4] It is regulated as a small-molecule prescription drug. A conventional generic tablet would generally pursue an ANDA, while a materially different dosage form may require a 505(b)(2) application.

FDA development priorities include:

• Comparative dissolution across strengths.
• Bioequivalence for both sacubitril-related and valsartan-related analytes.
• Impurity and degradation-product control.
• Stability under ICH conditions.
• Excipient safety and prior use.
• Pediatric acceptability where applicable.
• Consistency of dosage-unit content.

The highest-value excipient strategy is therefore one that improves regulatory reproducibility while maintaining a low-risk inactive-ingredient profile.

Key Takeaways

• Entresto uses a conventional immediate-release tablet platform based on microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, talc, and standard film-coating materials.
• The core technical risks are dual-active blend uniformity, dissolution control, moisture management, and strength-to-strength manufacturing consistency.
• The most attractive excipient opportunities are qualified second sources, direct-compression systems, low-moisture processing, coating platforms, and pediatric multiparticulate delivery.
• Entresto is a small molecule, so generic competition will use ANDA strategies rather than biosimilar pathways.
• Patent exposure centers on sacubitril/valsartan combination, pharmaceutical-composition, solid-state, method-of-use, and pediatric presentation claims.
• Standard excipients are unlikely to create a meaningful standalone patent barrier. Differentiated excipient systems must demonstrate technical and regulatory value.
• Entresto’s multibillion-dollar sales base supports substantial generic and supplier interest, but settlement timing and patent litigation can determine the commercial return on formulation investment.
• A conventional tablet is the lowest-risk entry. Sprinkle, orally disintegrating, liquid, and taste-masked products offer greater differentiation but may require a 505(b)(2) strategy.

FAQs

Can a generic Entresto product use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements.

Is Entresto a biologic requiring biosimilar competition?

No. Entresto is a small-molecule combination product containing sacubitril and valsartan. Competitive products would generally follow generic-drug pathways.

Which excipient is most important for Entresto tablet performance?

No single excipient controls performance. Microcrystalline cellulose, low-substituted hydroxypropylcellulose, crospovidone, and colloidal silicon dioxide collectively influence compression, flow, disintegration, and blend uniformity.

Can an excipient change avoid Entresto composition patents?

Usually not where a patent claims the active-ingredient combination, salt, complex, or method of treatment. Excipient changes are more relevant to narrow formulation or manufacturing claims.

Does the Entresto Sprinkle product create a separate commercial opportunity?

Yes. Pediatric multiparticulate delivery can support a differentiated product strategy, particularly where taste masking, dose flexibility, food compatibility, and swallowing ease are improved without compromising bioequivalence or stability.

References

1. U.S. Food and Drug Administration. (2024). Entresto (sacubitril and valsartan) prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,734,876: Pharmaceutical compositions comprising valsartan and sacubitril.

4. U.S. Food and Drug Administration. (2021). Entresto Sprinkle approval information and prescribing materials. Novartis Pharmaceuticals Corporation.

5. Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis.